Q2 2025 Elevance Health Inc Earnings Call Transcript
Key Points
- Elevance Health Inc (ELV) reported a 14% year-over-year increase in operating revenue, reaching $49.4 billion, driven by higher premium yields and recent acquisitions.
- The company delivered adjusted EPS consistent with expectations, reflecting strength in the Medicare Advantage portfolio and disciplined cost management.
- CarelonRx and Carelon services showed strong performance, with CarelonRx growing operating revenue by over 20% and Carelon services delivering more than 50% growth in revenue.
- Elevance Health Inc (ELV) is actively using AI-enabled tools to streamline clinical workflows and improve operational efficiency.
- The company is expanding its value-based care portfolio, particularly in behavioral health and oncology, with more than one-third of benefit expenses now in downside risk arrangements.
- Elevance Health Inc (ELV) revised its full-year 2025 adjusted EPS guidance to approximately $30, reflecting pressures from elevated medical cost trends in ACA and slower Medicaid rate alignment.
- The company experienced a sequential decline in medical membership, down approximately 200,000, primarily due to reductions in Medicaid membership and lower effectuation rates in the ACA business.
- The consolidated benefit expense ratio increased by 260 basis points year-over-year, driven by ACA and Medicaid businesses.
- Elevance Health Inc (ELV) is facing challenges with elevated medical cost trends due to increased morbidity in the ACA market and higher acuity from Medicaid redeterminations.
- The company anticipates a prolonged Medicaid margin recovery period due to slower-than-expected rate adjustments aligning with current cost levels.
Thanks, ladies and gentlemen. Thank you for standing by and welcome to the Elevance Health second-quarter earnings conference call. Later we will conduct a question-and-answer session. (Operator Instructions) As a reminder, today's conference is being recorded.
I would now like to turn the conference over to the company's management. Please go ahead.
Good morning, and welcome to Elevance Healthâs second-quarter 2025 earnings conference call. My name is Nathan Rich, Vice President of Investor Relations.
With us this morning on the earnings call are Gail Boudreaux, President and CEO; Mark Kaye, our CFO; Peter Haytaian, President of Carelon; Morgan Kendrick, President of our Commercial Health Benefits business; and Felicia Norwood, President of our Government Health Benefits business.
Gail will begin the call with a discussion of our second quarter performance and revised outlook as well as the progress we've made against our strategic initiatives. Mark will then
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
